| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 113 | 2024 | 15694 | 3.920 |
Why?
|
| Receptor, ErbB-2 | 30 | 2024 | 2518 | 2.070 |
Why?
|
| Diphosphonates | 12 | 2007 | 262 | 1.720 |
Why?
|
| Complementary Therapies | 6 | 2015 | 126 | 1.560 |
Why?
|
| Bone Neoplasms | 19 | 2014 | 2576 | 1.220 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2017 | 198 | 1.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 36 | 2024 | 15862 | 1.110 |
Why?
|
| Trastuzumab | 20 | 2023 | 696 | 0.970 |
Why?
|
| Neoplasms, Hormone-Dependent | 3 | 2013 | 342 | 0.930 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 140 | 0.800 |
Why?
|
| Antibodies, Monoclonal, Humanized | 17 | 2014 | 3251 | 0.770 |
Why?
|
| Drugs, Chinese Herbal | 4 | 2007 | 48 | 0.770 |
Why?
|
| Purines | 2 | 2017 | 273 | 0.660 |
Why?
|
| Female | 123 | 2024 | 141928 | 0.660 |
Why?
|
| Pain | 16 | 2011 | 1658 | 0.660 |
Why?
|
| Aminopyridines | 2 | 2017 | 212 | 0.650 |
Why?
|
| Molecular Targeted Therapy | 6 | 2020 | 2330 | 0.640 |
Why?
|
| Antineoplastic Agents | 24 | 2016 | 14289 | 0.640 |
Why?
|
| Clinical Protocols | 1 | 2020 | 467 | 0.630 |
Why?
|
| Neoplasms | 16 | 2018 | 15193 | 0.610 |
Why?
|
| Antibodies, Monoclonal | 14 | 2021 | 4367 | 0.590 |
Why?
|
| Randomized Controlled Trials as Topic | 14 | 2011 | 2594 | 0.580 |
Why?
|
| Phytotherapy | 3 | 2010 | 110 | 0.570 |
Why?
|
| Humans | 143 | 2024 | 261506 | 0.560 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2017 | 129 | 0.560 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2020 | 551 | 0.550 |
Why?
|
| Receptors, Estrogen | 10 | 2023 | 2086 | 0.550 |
Why?
|
| Quality Improvement | 1 | 2022 | 851 | 0.510 |
Why?
|
| Carcinoma, Lobular | 3 | 2024 | 611 | 0.510 |
Why?
|
| Deoxycytidine | 3 | 2007 | 1353 | 0.480 |
Why?
|
| Tamoxifen | 9 | 2020 | 876 | 0.470 |
Why?
|
| Neoadjuvant Therapy | 12 | 2020 | 4975 | 0.470 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 280 | 0.460 |
Why?
|
| Pyridines | 1 | 2020 | 1244 | 0.460 |
Why?
|
| Biomarkers, Tumor | 14 | 2017 | 10331 | 0.450 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2018 | 8873 | 0.440 |
Why?
|
| Bone Diseases | 1 | 2014 | 143 | 0.440 |
Why?
|
| Analgesics | 8 | 2011 | 390 | 0.410 |
Why?
|
| Breast | 3 | 2024 | 1344 | 0.410 |
Why?
|
| Piperazines | 1 | 2020 | 2101 | 0.400 |
Why?
|
| Treatment Outcome | 33 | 2020 | 32848 | 0.400 |
Why?
|
| Clinical Trials as Topic | 11 | 2015 | 3719 | 0.400 |
Why?
|
| Physician-Patient Relations | 3 | 2014 | 792 | 0.380 |
Why?
|
| Radiology | 2 | 2015 | 434 | 0.380 |
Why?
|
| Mammography | 3 | 2015 | 1010 | 0.380 |
Why?
|
| Plant Extracts | 3 | 2010 | 215 | 0.370 |
Why?
|
| Patient Compliance | 4 | 2012 | 667 | 0.370 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2024 | 10035 | 0.370 |
Why?
|
| Bridged-Ring Compounds | 3 | 2020 | 183 | 0.360 |
Why?
|
| Proto-Oncogene Proteins c-met | 3 | 2018 | 419 | 0.360 |
Why?
|
| Biological Therapy | 2 | 2012 | 58 | 0.350 |
Why?
|
| Drug Approval | 1 | 2010 | 178 | 0.350 |
Why?
|
| Genes, BRCA2 | 1 | 2011 | 309 | 0.340 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 332 | 0.340 |
Why?
|
| Middle Aged | 64 | 2024 | 86204 | 0.340 |
Why?
|
| Genes, BRCA1 | 1 | 2011 | 387 | 0.330 |
Why?
|
| Taxoids | 5 | 2020 | 967 | 0.320 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2016 | 479 | 0.320 |
Why?
|
| Everolimus | 3 | 2023 | 415 | 0.320 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2016 | 1248 | 0.320 |
Why?
|
| Geriatric Assessment | 3 | 2018 | 275 | 0.320 |
Why?
|
| Bone Density Conservation Agents | 2 | 2007 | 198 | 0.320 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 4757 | 0.320 |
Why?
|
| Disease-Free Survival | 16 | 2023 | 10001 | 0.320 |
Why?
|
| Administration, Oral | 10 | 2006 | 1544 | 0.310 |
Why?
|
| Aromatase Inhibitors | 2 | 2013 | 305 | 0.310 |
Why?
|
| Neoplasm Metastasis | 15 | 2015 | 5112 | 0.310 |
Why?
|
| Communication | 2 | 2014 | 876 | 0.310 |
Why?
|
| Antineoplastic Agents, Hormonal | 7 | 2021 | 840 | 0.300 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2022 | 1216 | 0.290 |
Why?
|
| Patient Selection | 6 | 2015 | 2055 | 0.280 |
Why?
|
| Lymphatic Metastasis | 4 | 2021 | 4844 | 0.280 |
Why?
|
| Tumor Burden | 5 | 2021 | 1987 | 0.270 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2002 | 1299 | 0.270 |
Why?
|
| Genetic Therapy | 2 | 2004 | 1616 | 0.270 |
Why?
|
| Oncogenes | 2 | 2004 | 673 | 0.270 |
Why?
|
| Refusal to Participate | 1 | 2005 | 2 | 0.270 |
Why?
|
| Triple Negative Breast Neoplasms | 3 | 2023 | 1215 | 0.260 |
Why?
|
| Carcinoma in Situ | 2 | 2023 | 487 | 0.260 |
Why?
|
| Aged | 45 | 2021 | 70117 | 0.260 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2004 | 1064 | 0.250 |
Why?
|
| Breast Neoplasms, Male | 3 | 2015 | 229 | 0.240 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 1533 | 0.240 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 1879 | 0.240 |
Why?
|
| Bevacizumab | 3 | 2016 | 938 | 0.230 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2004 | 212 | 0.230 |
Why?
|
| Breast Carcinoma In Situ | 1 | 2023 | 14 | 0.230 |
Why?
|
| Fluorouracil | 2 | 2007 | 1944 | 0.230 |
Why?
|
| Estrogens | 4 | 2013 | 751 | 0.230 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2023 | 76 | 0.230 |
Why?
|
| Survival Analysis | 10 | 2023 | 9180 | 0.230 |
Why?
|
| Immunologic Factors | 1 | 2007 | 649 | 0.220 |
Why?
|
| Postmenopause | 3 | 2021 | 378 | 0.220 |
Why?
|
| Medicine, Chinese Traditional | 1 | 2002 | 30 | 0.220 |
Why?
|
| Dietary Supplements | 2 | 2007 | 558 | 0.220 |
Why?
|
| Plants, Medicinal | 1 | 2002 | 44 | 0.220 |
Why?
|
| Drug Design | 1 | 2005 | 375 | 0.220 |
Why?
|
| Patient Participation | 2 | 2012 | 446 | 0.210 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 2 | 2011 | 30 | 0.210 |
Why?
|
| Karnofsky Performance Status | 3 | 2018 | 175 | 0.210 |
Why?
|
| Adult | 45 | 2021 | 77950 | 0.210 |
Why?
|
| Receptors, Progesterone | 5 | 2020 | 1392 | 0.210 |
Why?
|
| Triazoles | 3 | 2016 | 617 | 0.210 |
Why?
|
| Proportional Hazards Models | 8 | 2020 | 4988 | 0.200 |
Why?
|
| Technology | 1 | 2022 | 96 | 0.200 |
Why?
|
| Attitude to Health | 1 | 2005 | 465 | 0.200 |
Why?
|
| Nitriles | 3 | 2016 | 906 | 0.200 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2023 | 5178 | 0.200 |
Why?
|
| Cell Line, Tumor | 10 | 2024 | 14551 | 0.200 |
Why?
|
| Receptors, CXCR4 | 1 | 2023 | 269 | 0.200 |
Why?
|
| Interprofessional Relations | 1 | 2003 | 213 | 0.190 |
Why?
|
| Mitosis | 1 | 2023 | 615 | 0.190 |
Why?
|
| Drug Delivery Systems | 1 | 2005 | 669 | 0.190 |
Why?
|
| Gene Amplification | 5 | 2018 | 731 | 0.190 |
Why?
|
| Gangliosides | 1 | 2021 | 95 | 0.190 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 709 | 0.180 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 2173 | 0.180 |
Why?
|
| Patient Education as Topic | 5 | 2005 | 748 | 0.180 |
Why?
|
| Research Design | 5 | 2020 | 1544 | 0.180 |
Why?
|
| Aged, 80 and over | 18 | 2020 | 29902 | 0.180 |
Why?
|
| Self Care | 4 | 2007 | 224 | 0.180 |
Why?
|
| Mastectomy, Segmental | 3 | 2020 | 1026 | 0.180 |
Why?
|
| Cell Cycle | 3 | 2017 | 2084 | 0.180 |
Why?
|
| Plasma | 1 | 2020 | 158 | 0.180 |
Why?
|
| Heart Diseases | 3 | 2004 | 732 | 0.170 |
Why?
|
| Estradiol | 2 | 2013 | 748 | 0.170 |
Why?
|
| Prognosis | 11 | 2023 | 21713 | 0.170 |
Why?
|
| Pain Management | 4 | 2007 | 668 | 0.170 |
Why?
|
| Neutropenia | 1 | 2023 | 968 | 0.160 |
Why?
|
| Mammaplasty | 3 | 2024 | 780 | 0.160 |
Why?
|
| Internet | 2 | 2014 | 706 | 0.160 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2018 | 142 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2015 | 6207 | 0.160 |
Why?
|
| RNA, Long Noncoding | 1 | 2024 | 598 | 0.160 |
Why?
|
| Signal Transduction | 7 | 2021 | 11965 | 0.160 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2002 | 852 | 0.160 |
Why?
|
| Apoptosis | 4 | 2023 | 7591 | 0.160 |
Why?
|
| Research | 2 | 2015 | 415 | 0.160 |
Why?
|
| Multivariate Analysis | 5 | 2018 | 4298 | 0.150 |
Why?
|
| Cell Proliferation | 6 | 2018 | 7226 | 0.150 |
Why?
|
| Patient Care Team | 1 | 2003 | 795 | 0.150 |
Why?
|
| Indazoles | 1 | 2018 | 297 | 0.150 |
Why?
|
| Mastectomy | 4 | 2024 | 1534 | 0.150 |
Why?
|
| Biomarkers | 3 | 2019 | 5047 | 0.140 |
Why?
|
| Genes, erbB-2 | 3 | 2004 | 229 | 0.140 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 521 | 0.140 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2017 | 112 | 0.140 |
Why?
|
| Vitamin D Deficiency | 1 | 2017 | 115 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 2403 | 0.140 |
Why?
|
| Fractures, Bone | 2 | 2017 | 291 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2021 | 3890 | 0.140 |
Why?
|
| Combined Modality Therapy | 8 | 2015 | 8865 | 0.140 |
Why?
|
| Metabolome | 1 | 2019 | 344 | 0.140 |
Why?
|
| Disease Progression | 10 | 2016 | 6682 | 0.140 |
Why?
|
| Infusions, Intravenous | 5 | 2006 | 1382 | 0.140 |
Why?
|
| Neoplasm Staging | 11 | 2019 | 13658 | 0.140 |
Why?
|
| Mandatory Reporting | 1 | 2015 | 24 | 0.140 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2023 | 882 | 0.140 |
Why?
|
| Femoral Fractures | 1 | 2016 | 50 | 0.140 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2014 | 607 | 0.130 |
Why?
|
| Cyclophosphamide | 6 | 2020 | 3001 | 0.130 |
Why?
|
| Pain, Intractable | 2 | 2011 | 171 | 0.130 |
Why?
|
| Placebos | 3 | 2005 | 437 | 0.130 |
Why?
|
| ErbB Receptors | 1 | 2004 | 2295 | 0.130 |
Why?
|
| Morbidity | 3 | 2004 | 397 | 0.120 |
Why?
|
| Psychophysiology | 2 | 2007 | 16 | 0.120 |
Why?
|
| Capecitabine | 2 | 2024 | 388 | 0.120 |
Why?
|
| Paclitaxel | 5 | 2019 | 1996 | 0.120 |
Why?
|
| Bone Resorption | 3 | 2005 | 138 | 0.120 |
Why?
|
| Outpatients | 2 | 2011 | 462 | 0.120 |
Why?
|
| Doxorubicin | 6 | 2020 | 3005 | 0.120 |
Why?
|
| Maytansine | 1 | 2014 | 38 | 0.120 |
Why?
|
| Resistance Training | 1 | 2014 | 42 | 0.120 |
Why?
|
| Mutation | 3 | 2018 | 15179 | 0.120 |
Why?
|
| Receptors, Growth Factor | 1 | 1994 | 157 | 0.120 |
Why?
|
| Patient Care Planning | 1 | 2015 | 297 | 0.110 |
Why?
|
| Survivors | 3 | 2014 | 1031 | 0.110 |
Why?
|
| Carboplatin | 1 | 2016 | 823 | 0.110 |
Why?
|
| Awareness | 1 | 2014 | 126 | 0.110 |
Why?
|
| Growth Substances | 1 | 1994 | 300 | 0.110 |
Why?
|
| Quinolines | 1 | 2016 | 383 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 4 | 2011 | 543 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2016 | 428 | 0.110 |
Why?
|
| Cognitive Dysfunction | 1 | 2018 | 333 | 0.110 |
Why?
|
| Dementia | 1 | 2018 | 453 | 0.110 |
Why?
|
| Prospective Studies | 5 | 2024 | 12873 | 0.110 |
Why?
|
| Premenopause | 2 | 2021 | 131 | 0.110 |
Why?
|
| Androstadienes | 1 | 2013 | 165 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 1 | 2021 | 1443 | 0.110 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2018 | 923 | 0.110 |
Why?
|
| Sarcoma | 1 | 2023 | 1725 | 0.110 |
Why?
|
| Receptors, Steroid | 3 | 2021 | 286 | 0.110 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 2864 | 0.110 |
Why?
|
| Tubulin Modulators | 1 | 2012 | 65 | 0.110 |
Why?
|
| Animals | 11 | 2024 | 59536 | 0.110 |
Why?
|
| Ribonucleotide Reductases | 2 | 2002 | 51 | 0.110 |
Why?
|
| Gene Expression Profiling | 6 | 2021 | 5159 | 0.110 |
Why?
|
| Cohort Studies | 4 | 2023 | 9244 | 0.100 |
Why?
|
| Decision Making | 2 | 2015 | 1287 | 0.100 |
Why?
|
| Receptors, Androgen | 1 | 2017 | 878 | 0.100 |
Why?
|
| Perception | 1 | 2014 | 350 | 0.100 |
Why?
|
| Proto-Oncogenes | 1 | 1992 | 202 | 0.100 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 1249 | 0.100 |
Why?
|
| Mice | 7 | 2024 | 34495 | 0.100 |
Why?
|
| Data Collection | 1 | 2014 | 620 | 0.100 |
Why?
|
| Microtubules | 1 | 2012 | 270 | 0.100 |
Why?
|
| Scutellaria | 2 | 2010 | 6 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2020 | 7702 | 0.100 |
Why?
|
| Drug Administration Schedule | 5 | 2004 | 3472 | 0.100 |
Why?
|
| Metabolic Syndrome | 1 | 2014 | 353 | 0.090 |
Why?
|
| Retrospective Studies | 7 | 2023 | 37905 | 0.090 |
Why?
|
| United States | 4 | 2015 | 15433 | 0.090 |
Why?
|
| Risk Assessment | 5 | 2019 | 6869 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 622 | 0.090 |
Why?
|
| Biopsy | 2 | 2015 | 3443 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2018 | 1823 | 0.090 |
Why?
|
| Glycoproteins | 1 | 2013 | 747 | 0.090 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2010 | 447 | 0.090 |
Why?
|
| Sirolimus | 1 | 2013 | 814 | 0.090 |
Why?
|
| Glycogen Storage Disease Type II | 1 | 1988 | 14 | 0.090 |
Why?
|
| Male | 19 | 2018 | 123000 | 0.080 |
Why?
|
| Heart Block | 1 | 1988 | 48 | 0.080 |
Why?
|
| alpha-Glucosidases | 1 | 1988 | 55 | 0.080 |
Why?
|
| Quinazolines | 1 | 2013 | 923 | 0.080 |
Why?
|
| Case-Control Studies | 5 | 2020 | 6100 | 0.080 |
Why?
|
| Sensitivity and Specificity | 3 | 2012 | 4971 | 0.080 |
Why?
|
| Oxygen | 1 | 2012 | 754 | 0.080 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2008 | 84 | 0.080 |
Why?
|
| Medical Oncology | 2 | 2015 | 1423 | 0.080 |
Why?
|
| Enzyme Activation | 2 | 2013 | 1764 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 598 | 0.080 |
Why?
|
| Anthracyclines | 2 | 2011 | 331 | 0.080 |
Why?
|
| Safety | 3 | 2004 | 465 | 0.070 |
Why?
|
| Acupuncture | 1 | 2007 | 22 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2011 | 665 | 0.070 |
Why?
|
| Cell Movement | 4 | 2021 | 2466 | 0.070 |
Why?
|
| DNA Fragmentation | 1 | 2006 | 198 | 0.070 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2011 | 502 | 0.070 |
Why?
|
| Phosphorylation | 4 | 2018 | 4804 | 0.070 |
Why?
|
| Exercise | 1 | 2014 | 1183 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2018 | 3518 | 0.070 |
Why?
|
| Nursing Methodology Research | 1 | 2005 | 18 | 0.070 |
Why?
|
| Flow Cytometry | 2 | 2014 | 3033 | 0.070 |
Why?
|
| Neoplasm Grading | 3 | 2015 | 1742 | 0.060 |
Why?
|
| Mastectomy, Radical | 1 | 2004 | 39 | 0.060 |
Why?
|
| Poisson Distribution | 1 | 2004 | 91 | 0.060 |
Why?
|
| Medical Records | 2 | 2005 | 415 | 0.060 |
Why?
|
| Cell Adhesion | 2 | 2021 | 1008 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2013 | 2022 | 0.060 |
Why?
|
| Pain Measurement | 5 | 2011 | 953 | 0.060 |
Why?
|
| Double-Blind Method | 3 | 2006 | 2588 | 0.060 |
Why?
|
| I-kappa B Kinase | 1 | 2005 | 250 | 0.060 |
Why?
|
| Quality of Life | 6 | 2014 | 4532 | 0.060 |
Why?
|
| Caspases | 1 | 2006 | 661 | 0.060 |
Why?
|
| Ethics, Research | 1 | 2004 | 67 | 0.060 |
Why?
|
| Mice, SCID | 2 | 2021 | 1869 | 0.060 |
Why?
|
| Pyroptosis | 1 | 2024 | 22 | 0.060 |
Why?
|
| Risk Factors | 6 | 2019 | 17523 | 0.060 |
Why?
|
| Time Factors | 7 | 2015 | 12926 | 0.060 |
Why?
|
| Surveys and Questionnaires | 5 | 2012 | 5687 | 0.060 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2004 | 106 | 0.060 |
Why?
|
| Ovariectomy | 1 | 2004 | 330 | 0.060 |
Why?
|
| Cyclin D1 | 1 | 2005 | 576 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 4549 | 0.060 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2012 | 573 | 0.060 |
Why?
|
| Receptors, Cell Surface | 1 | 2006 | 862 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2005 | 556 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 2002 | 5395 | 0.050 |
Why?
|
| Soy Foods | 1 | 2002 | 14 | 0.050 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2003 | 116 | 0.050 |
Why?
|
| Oncology Nursing | 1 | 2002 | 51 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2018 | 7548 | 0.050 |
Why?
|
| Predictive Value of Tests | 5 | 2015 | 4892 | 0.050 |
Why?
|
| Myocardium | 1 | 1988 | 1313 | 0.050 |
Why?
|
| Comorbidity | 2 | 2019 | 2352 | 0.050 |
Why?
|
| RNA Splicing | 1 | 2024 | 370 | 0.050 |
Why?
|
| Bayes Theorem | 2 | 2016 | 1021 | 0.050 |
Why?
|
| Home Care Services | 1 | 2002 | 92 | 0.050 |
Why?
|
| Ethics, Medical | 1 | 2005 | 442 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 6009 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2023 | 666 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 3821 | 0.050 |
Why?
|
| Mass Screening | 1 | 2009 | 1509 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2018 | 2232 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2002 | 566 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2004 | 435 | 0.050 |
Why?
|
| Transcriptome | 2 | 2023 | 1859 | 0.050 |
Why?
|
| Quality of Health Care | 2 | 2003 | 621 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2006 | 691 | 0.050 |
Why?
|
| Diet Therapy | 1 | 2001 | 52 | 0.050 |
Why?
|
| Water | 1 | 2002 | 361 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2002 | 503 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 3981 | 0.050 |
Why?
|
| Acupuncture Therapy | 1 | 2001 | 89 | 0.050 |
Why?
|
| Cell Division | 2 | 2002 | 2489 | 0.050 |
Why?
|
| Patient Satisfaction | 2 | 2003 | 915 | 0.040 |
Why?
|
| Caregivers | 2 | 2003 | 677 | 0.040 |
Why?
|
| Incidence | 3 | 2016 | 5673 | 0.040 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2002 | 494 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2005 | 697 | 0.040 |
Why?
|
| Mice, Nude | 3 | 2021 | 4307 | 0.040 |
Why?
|
| Sex Factors | 1 | 2004 | 2139 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2019 | 2054 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2015 | 1323 | 0.040 |
Why?
|
| Sickness Impact Profile | 1 | 2019 | 139 | 0.040 |
Why?
|
| Mexican Americans | 1 | 2020 | 322 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2006 | 1390 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2005 | 918 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 4849 | 0.040 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 146 | 0.040 |
Why?
|
| Heart | 1 | 2004 | 1223 | 0.040 |
Why?
|
| California | 2 | 2012 | 208 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2003 | 4938 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2011 | 5270 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2001 | 636 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2003 | 1085 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 4557 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 336 | 0.040 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 4320 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 5767 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2005 | 1303 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 538 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2004 | 1270 | 0.030 |
Why?
|
| Heart Failure | 2 | 2013 | 2516 | 0.030 |
Why?
|
| Texas | 2 | 2017 | 6311 | 0.030 |
Why?
|
| Drug Resistance | 2 | 1994 | 587 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 904 | 0.030 |
Why?
|
| Metabolomics | 1 | 2019 | 478 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 3639 | 0.030 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2014 | 35 | 0.030 |
Why?
|
| Diagnostic Imaging | 2 | 2014 | 1162 | 0.030 |
Why?
|
| Registries | 2 | 2014 | 2170 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2003 | 1209 | 0.030 |
Why?
|
| Biosynthetic Pathways | 1 | 2014 | 46 | 0.030 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2009 | 500 | 0.030 |
Why?
|
| Psychometrics | 1 | 2019 | 937 | 0.030 |
Why?
|
| Hospitals | 1 | 2017 | 485 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2000 | 899 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2019 | 2316 | 0.030 |
Why?
|
| Stress Fibers | 1 | 2013 | 15 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2014 | 140 | 0.030 |
Why?
|
| Palliative Care | 2 | 2002 | 2037 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2014 | 392 | 0.030 |
Why?
|
| Physical Fitness | 1 | 2014 | 122 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2020 | 1529 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 799 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2013 | 67 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2013 | 166 | 0.030 |
Why?
|
| Racism | 1 | 2013 | 50 | 0.030 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2009 | 674 | 0.030 |
Why?
|
| Neoplasm, Residual | 2 | 2011 | 1656 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2003 | 573 | 0.030 |
Why?
|
| Transfection | 2 | 2015 | 2944 | 0.030 |
Why?
|
| Adenocarcinoma | 2 | 2006 | 7789 | 0.030 |
Why?
|
| Cell Survival | 1 | 2018 | 3045 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2002 | 1371 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2015 | 324 | 0.030 |
Why?
|
| Cytoskeleton | 1 | 2013 | 267 | 0.030 |
Why?
|
| Phosphotransferases | 1 | 1992 | 84 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2015 | 1163 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 2013 | 244 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 577 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2011 | 120 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2011 | 1945 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 1992 | 141 | 0.030 |
Why?
|
| Physician's Role | 1 | 2014 | 238 | 0.030 |
Why?
|
| Young Adult | 3 | 2015 | 21445 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2013 | 553 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 11538 | 0.020 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 1992 | 129 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 460 | 0.020 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 1763 | 0.020 |
Why?
|
| Cisplatin | 1 | 1998 | 2432 | 0.020 |
Why?
|
| Program Evaluation | 2 | 2004 | 597 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 3869 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2017 | 1678 | 0.020 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2009 | 1415 | 0.020 |
Why?
|
| Fibroblasts | 2 | 2005 | 1682 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1992 | 311 | 0.020 |
Why?
|
| Genes, myc | 1 | 1992 | 358 | 0.020 |
Why?
|
| Statistics, Nonparametric | 2 | 2004 | 980 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1992 | 402 | 0.020 |
Why?
|
| Delayed Diagnosis | 1 | 2011 | 144 | 0.020 |
Why?
|
| Palpation | 1 | 2009 | 49 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2011 | 397 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 1062 | 0.020 |
Why?
|
| Membranes | 1 | 1988 | 31 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2020 | 2967 | 0.020 |
Why?
|
| Gene Expression | 1 | 2017 | 3570 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 661 | 0.020 |
Why?
|
| Remission Induction | 1 | 2015 | 3569 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 1489 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2012 | 592 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2013 | 810 | 0.020 |
Why?
|
| Phenotype | 2 | 2015 | 6295 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 4314 | 0.020 |
Why?
|
| Nutrition Assessment | 1 | 2009 | 169 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2015 | 2218 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2014 | 1506 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 1217 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 1992 | 783 | 0.020 |
Why?
|
| Muscles | 1 | 1988 | 416 | 0.020 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 3230 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2009 | 299 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 3441 | 0.020 |
Why?
|
| Ultrasonography, Mammary | 1 | 2009 | 380 | 0.020 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2006 | 107 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 1290 | 0.020 |
Why?
|
| Lysosomes | 1 | 1988 | 347 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2011 | 973 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 1130 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2006 | 348 | 0.020 |
Why?
|
| Contrast Media | 1 | 2012 | 1472 | 0.020 |
Why?
|
| Tape Recording | 1 | 2005 | 14 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 3536 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 5377 | 0.020 |
Why?
|
| Alleles | 1 | 1992 | 2437 | 0.020 |
Why?
|
| Flavonoids | 1 | 2006 | 188 | 0.020 |
Why?
|
| Affect | 1 | 2007 | 288 | 0.020 |
Why?
|
| Nurse-Patient Relations | 1 | 2004 | 23 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 611 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2009 | 674 | 0.020 |
Why?
|
| International Cooperation | 1 | 2005 | 323 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 591 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2009 | 2231 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2009 | 1581 | 0.010 |
Why?
|
| Recurrence | 1 | 2012 | 4758 | 0.010 |
Why?
|
| Creatinine | 1 | 2006 | 531 | 0.010 |
Why?
|
| Toremifene | 1 | 2003 | 8 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 1258 | 0.010 |
Why?
|
| Plasmids | 1 | 2005 | 837 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2006 | 1519 | 0.010 |
Why?
|
| Liposomes | 1 | 2005 | 684 | 0.010 |
Why?
|
| Clinical Nursing Research | 1 | 2002 | 8 | 0.010 |
Why?
|
| Cytogenetic Analysis | 1 | 2004 | 568 | 0.010 |
Why?
|
| Videotape Recording | 1 | 2003 | 74 | 0.010 |
Why?
|
| Community-Institutional Relations | 1 | 2003 | 42 | 0.010 |
Why?
|
| DNA Repair | 1 | 2010 | 1872 | 0.010 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2003 | 112 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1992 | 2488 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2011 | 2291 | 0.010 |
Why?
|
| Thyroid Hormones | 1 | 2003 | 111 | 0.010 |
Why?
|
| Internal-External Control | 1 | 2002 | 110 | 0.010 |
Why?
|
| Education, Nursing | 1 | 2002 | 18 | 0.010 |
Why?
|
| North Carolina | 1 | 2001 | 125 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1994 | 7222 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 1363 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 5539 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2007 | 1819 | 0.010 |
Why?
|
| Piperidines | 1 | 2006 | 1035 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2004 | 1471 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2004 | 1681 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2006 | 14889 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2005 | 1620 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 1037 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 3203 | 0.010 |
Why?
|
| Prevalence | 1 | 2007 | 3260 | 0.010 |
Why?
|
| Health Behavior | 1 | 2002 | 603 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 1999 | 756 | 0.010 |
Why?
|
| Fever | 1 | 2001 | 497 | 0.010 |
Why?
|
| Cell Line | 1 | 2005 | 5114 | 0.010 |
Why?
|
| Adolescent | 2 | 2006 | 31252 | 0.010 |
Why?
|
| Kidney | 1 | 2006 | 2146 | 0.010 |
Why?
|
| General Surgery | 1 | 2000 | 326 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2000 | 2803 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2001 | 2054 | 0.010 |
Why?
|